Loading stock data…
ANI Pharmaceuticals (ANIP)
$84.50+1.22 (+1.46%)
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ANI Pharmaceuticals, Inc. in the Healthcare sector is trading at $84.50 with a market capitalization of $1.9B. Wall Street consensus targets $112.71 (7 analysts), implying a +33.4% move over the next 12 months. The stock is currently 15% below its 52-week high of $99.50, remaining 2.1% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +33.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $237.46M↓ | $247.06M↑ | $227.81M↑ | $211.37M↑ | $197.12M |
| Gross Profit | $143.88M↓ | $146.79M↑ | $134.42M↓ | $136.76M↑ | $124.08M |
| Operating Income | $38.71M↑ | $29.13M↑ | $22.83M↑ | $15.17M↑ | $14.10M |
| Net Income | $29.49M↑ | $27.49M↑ | $26.62M↑ | $8.55M↓ | $15.68M |
Peer Comparison
JNJUNHPFE
Fundamentals
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.88B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
16.39%
Volume
Today's trading volume
780,606
Recent News
How Is Viatris’ Stock Performance Compared to Other Healthcare Stocks?
Viatris has outperformed its industry peers over the past year, and Wall Street appears optimistic about the stock.
Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings?
ANIP trades at 9.75x forward earnings after raising 2026 guidance, but investors must weigh Cortrophin-led growth against competition and customer concentration.
ANI Pharmaceuticals Targets Acute Gout With Cortrophin Push
ANIP expands Cortrophin into acute gout flares with a 90-person sales force as investors watch adoption, spending and 2026 milestones.
2 Cash-Producing Stocks to Research Further and 1 Facing Challenges
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
How ANI’s Estradiol Gel Recall at ANI Pharmaceuticals (ANIP) Has Changed Its Quality-Control Investment Story
In May 2026, ANI Pharmaceuticals, Inc. voluntarily initiated an FDA Class II nationwide recall of 3,964 cartons of Estradiol Gel 0.1% (Lot M251109, expiring November 2027) after defective single-dose packets were found to be empty or only partially filled. This packaging failure raises questions about quality control and operational robustness at a time when ANI is otherwise emphasizing execution strength across its branded and generics portfolio. We’ll now examine how this Estradiol Gel...